Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX6, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
NCT00193219Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2005
- Primary completion
- Jun 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of KL-140 in colorectal cancer (metastatic) (mCRC), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 18 months. Started Jul 2005; status: completed.
02
Drugs
KL-140
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00193219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193219.